Trial Profile
Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Jan 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Thromboembolism
- Focus Pharmacodynamics; Therapeutic Use
- 10 Jan 2019 Planned number of patients changed from 120 to 150.
- 12 Nov 2018 Results published in the Drugs and Aging
- 05 Jul 2018 Status changed from recruiting to completed.